EA201690205A1 - Сайт-специфические химико-ферментативные модификации белков - Google Patents
Сайт-специфические химико-ферментативные модификации белковInfo
- Publication number
- EA201690205A1 EA201690205A1 EA201690205A EA201690205A EA201690205A1 EA 201690205 A1 EA201690205 A1 EA 201690205A1 EA 201690205 A EA201690205 A EA 201690205A EA 201690205 A EA201690205 A EA 201690205A EA 201690205 A1 EA201690205 A1 EA 201690205A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- proteins
- site
- enmentative
- modifications
- specific chemical
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 238000012986 modification Methods 0.000 title 1
- 108060008539 Transglutaminase Proteins 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000006911 enzymatic reaction Methods 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000009145 protein modification Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 102000003601 transglutaminase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D229/00—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms
- C07D229/02—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms containing three-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/08—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845273P | 2013-07-11 | 2013-07-11 | |
| US201462016044P | 2014-06-23 | 2014-06-23 | |
| PCT/US2014/046409 WO2015006728A2 (en) | 2013-07-11 | 2014-07-11 | Site-specific chemoenzymatic protein modifications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201690205A1 true EA201690205A1 (ru) | 2016-12-30 |
Family
ID=51298955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690205A EA201690205A1 (ru) | 2013-07-11 | 2014-07-11 | Сайт-специфические химико-ферментативные модификации белков |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9359400B2 (enExample) |
| EP (2) | EP3613755A1 (enExample) |
| JP (1) | JP6739333B2 (enExample) |
| KR (1) | KR20160040556A (enExample) |
| CN (1) | CN105593238B (enExample) |
| AU (1) | AU2014286990A1 (enExample) |
| BR (1) | BR112016000585A2 (enExample) |
| CA (1) | CA2918076A1 (enExample) |
| EA (1) | EA201690205A1 (enExample) |
| ES (1) | ES2756526T3 (enExample) |
| MX (1) | MX2016000393A (enExample) |
| WO (1) | WO2015006728A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016000585A2 (pt) * | 2013-07-11 | 2018-03-20 | Novartis Ag | modificações quimioenzimáticas sítio-específicas de proteína |
| US10588980B2 (en) * | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| MX2018007451A (es) * | 2015-12-18 | 2018-11-09 | Eisai R&D Man Co Ltd | Inmunoglobulinas conjugadas con lisina c-terminal. |
| EP3436061A4 (en) | 2016-03-31 | 2019-12-04 | Liffey Biotech Limited | Saccharide-polypeptide-conjugate compositions and methods of use thereof |
| CA3026991A1 (en) | 2016-06-10 | 2017-12-14 | Eisai R&D Management Co., Ltd. | Lysine conjugated immunoglobulins |
| RS65362B1 (sr) | 2016-09-02 | 2024-04-30 | Sanofi Pasteur Inc | Vakcina protiv neisseria meningitidis |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| MX2019007910A (es) | 2016-12-30 | 2019-12-05 | Sutrovax Inc | Conjugados de polipeptido-antigeno con aminoacidos no naturales. |
| EP3691677A4 (en) | 2017-10-04 | 2021-07-07 | Pogona, Llc | COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE |
| MX2021008821A (es) * | 2019-01-25 | 2021-08-24 | Avedro Inc | Derivados de bis (diazirina) como foto-reticulante para el tratamiento de trastornos ectasicos de cornea. |
| EP4540263A2 (en) * | 2022-06-16 | 2025-04-23 | The General Hospital Corporation | Bicyclononyne reagents for cell imaging |
| CN119375471A (zh) * | 2023-07-26 | 2025-01-28 | 菲鹏生物股份有限公司 | 抗体和抗体缀合物及其用途 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPH0665280B2 (ja) | 1987-03-04 | 1994-08-24 | 味の素株式会社 | タンパクゲル化剤及びそれを用いるタンパクのゲル化方法 |
| DE4022267C2 (de) * | 1990-07-12 | 1994-09-15 | Degussa | N-Acyldipeptide und deren Verwendung |
| JP2849773B2 (ja) | 1990-08-27 | 1999-01-27 | 天野製薬株式会社 | ストレプトミセス属由来のトランスグルタミナーゼの製造法 |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| US5425946A (en) | 1992-08-31 | 1995-06-20 | North American Vaccine, Inc. | Vaccines against group C Neisseria meningitidis |
| JP4097691B2 (ja) | 1992-08-31 | 2008-06-11 | バクスター、ヘルスケア、ソシエテ、アノニム | Ｃ群髄膜炎菌に対するワクチン |
| US5508191A (en) | 1993-07-05 | 1996-04-16 | Takeda Chemical Industries, Ltd. | Mutant strains of agrobacterium for producing β-1,3-glucan |
| DE69535037T2 (de) | 1994-08-26 | 2006-12-07 | Novozymes A/S | Mikrobielle transglutaminasen, ihre herstellung und ihre verwendung |
| EP0785276A4 (en) | 1994-09-29 | 2002-01-09 | Ajinomoto Kk | MODIFICATION OF A PEPTIDE AND A PROTEIN |
| EP0871712B1 (en) | 1995-01-19 | 2003-08-27 | Novozymes A/S | Transglutaminases from oomycetes |
| JP3669390B2 (ja) | 1995-02-09 | 2005-07-06 | 味の素株式会社 | バチルス属細菌由来のトランスグルタミナーゼ |
| US6284884B1 (en) | 1995-06-07 | 2001-09-04 | North American Vaccine, Inc. | Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof |
| EP0815833B1 (en) * | 1996-06-24 | 2003-04-09 | Givaudan SA | Malodour preventing agents |
| EP0950665A4 (en) | 1996-09-26 | 2004-05-06 | Ajinomoto Kk | PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| US6919076B1 (en) | 1998-01-20 | 2005-07-19 | Pericor Science, Inc. | Conjugates of agents and transglutaminase substrate linking molecules |
| CA2318661A1 (en) | 1998-01-20 | 1999-07-22 | Howard Green | Transglutaminase linkage of agents to tissue |
| US6958148B1 (en) | 1998-01-20 | 2005-10-25 | Pericor Science, Inc. | Linkage of agents to body tissue using microparticles and transglutaminase |
| US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| PT2332581E (pt) | 2001-01-23 | 2015-10-16 | Sanofi Pasteur Inc | Vacina meningocócica tri- ou tetravalente de conjugados de polissacárido e crm-197 |
| US7605175B2 (en) | 2001-03-02 | 2009-10-20 | Gpc Biotech Ag | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| JP2003199569A (ja) | 2001-12-17 | 2003-07-15 | Food Industry Research & Development Inst | ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ |
| DK1777236T3 (en) | 2002-03-26 | 2017-02-27 | Glaxosmithkline Biologicals Sa | MODIFIED SUCCARIDES WHICH IMPROVED WATER STABILITY FOR USE AS A MEDICINE |
| GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| EP1787661A1 (en) | 2004-09-10 | 2007-05-23 | Toray Industries, Inc. | Medicinal preparation |
| CN101107010A (zh) | 2004-11-01 | 2008-01-16 | 布里格海姆妇女医院公司 | 经修饰的链球菌多糖及其用途 |
| GB0502096D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
| EP1893239A2 (en) * | 2005-06-15 | 2008-03-05 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of growth hormone |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| US8586532B2 (en) * | 2007-08-24 | 2013-11-19 | Novo Nordisk Healthcare A/G | Method for selectively modifying a protein via transglutaminase catalyzed reaction |
| WO2009032247A1 (en) * | 2007-08-30 | 2009-03-12 | Northwestern University | Synthetic peptide and peptide conjugates and related tissue coupling methods via transglutaminase enzyme |
| DE102007044296A1 (de) * | 2007-09-17 | 2009-03-19 | Hans-Lothar Prof. Dr. Fuchsbauer | Strukturmodulator von Proteinen |
| US8137925B2 (en) * | 2007-11-09 | 2012-03-20 | Massachusetts Institute Of Technology | Methods and compositions for protein labeling using lipoic acid ligases |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| WO2010002042A1 (ja) * | 2008-07-04 | 2010-01-07 | 国立大学法人 九州大学 | タンパク質ラベル化用酵素基質 |
| JP2012518029A (ja) * | 2009-02-19 | 2012-08-09 | ノヴォ・ノルディスク・アー／エス | 第ｖｉｉｉ因子の修飾 |
| FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| WO2011002852A2 (en) | 2009-06-30 | 2011-01-06 | The Regents Of The University Of Michigan | Pro-drug complexes and related methods of use |
| US20110020837A1 (en) | 2009-07-07 | 2011-01-27 | Universiteit Utrecht Holding B.V. | Method for isolating or identifying a target protein interacting with a lipid in a cell |
| US8765920B2 (en) | 2009-12-23 | 2014-07-01 | The Scripps Research Institute | Tyrosine bioconjugation through aqueous Ene-like reactions |
| EP2894142B1 (en) * | 2010-04-27 | 2019-06-12 | SynAffix B.V. | Fused cyclooctyne compounds and their use in metal-free click reactions |
| EP2591354B1 (en) | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| WO2012004419A2 (en) | 2010-07-09 | 2012-01-12 | Université De Bretagne Occidentale | Modular construction of lipophospholipids |
| WO2012058635A1 (en) | 2010-10-29 | 2012-05-03 | Life Technologies Corporation | Biotin derivatives |
| CA2930801C (en) | 2010-11-05 | 2019-05-28 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| AU2011338615B2 (en) | 2010-12-07 | 2017-07-27 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
| CA2814953A1 (en) | 2010-12-13 | 2012-06-21 | Immunomedics, Inc. | Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules |
| WO2012142659A1 (en) | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
| FR2981352B1 (fr) * | 2011-10-17 | 2015-07-03 | Centre Nat Rech Scient | Procede de synthese de proteines |
| WO2013078564A2 (en) * | 2011-12-01 | 2013-06-06 | Angiochem Inc. | Targeted lysosomal enzyme compounds |
| JP5509440B2 (ja) * | 2012-06-22 | 2014-06-04 | 国立大学法人九州大学 | タンパク質−核酸複合体の製造方法および標的物の検出方法 |
| JP6744212B2 (ja) * | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | ポリペプチドの酵素的結合 |
| BR112016000585A2 (pt) | 2013-07-11 | 2018-03-20 | Novartis Ag | modificações quimioenzimáticas sítio-específicas de proteína |
-
2014
- 2014-07-11 BR BR112016000585A patent/BR112016000585A2/pt not_active Application Discontinuation
- 2014-07-11 EP EP19187438.7A patent/EP3613755A1/en not_active Withdrawn
- 2014-07-11 EP EP14748350.7A patent/EP3019515B1/en active Active
- 2014-07-11 AU AU2014286990A patent/AU2014286990A1/en not_active Abandoned
- 2014-07-11 WO PCT/US2014/046409 patent/WO2015006728A2/en not_active Ceased
- 2014-07-11 CA CA2918076A patent/CA2918076A1/en not_active Abandoned
- 2014-07-11 KR KR1020167003053A patent/KR20160040556A/ko not_active Withdrawn
- 2014-07-11 MX MX2016000393A patent/MX2016000393A/es unknown
- 2014-07-11 US US14/329,758 patent/US9359400B2/en active Active
- 2014-07-11 ES ES14748350T patent/ES2756526T3/es active Active
- 2014-07-11 JP JP2016525817A patent/JP6739333B2/ja active Active
- 2014-07-11 CN CN201480046805.8A patent/CN105593238B/zh active Active
- 2014-07-11 EA EA201690205A patent/EA201690205A1/ru unknown
-
2016
- 2016-05-02 US US15/144,397 patent/US20160237116A1/en not_active Abandoned
-
2018
- 2018-11-29 US US16/204,557 patent/US10975120B2/en active Active
-
2021
- 2021-04-12 US US17/228,284 patent/US20220089639A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3019515B1 (en) | 2019-08-21 |
| EP3019515A2 (en) | 2016-05-18 |
| KR20160040556A (ko) | 2016-04-14 |
| WO2015006728A3 (en) | 2015-03-12 |
| US20190300570A1 (en) | 2019-10-03 |
| AU2014286990A1 (en) | 2016-02-11 |
| US20220089639A1 (en) | 2022-03-24 |
| CN105593238B (zh) | 2020-09-08 |
| CA2918076A1 (en) | 2015-01-15 |
| ES2756526T3 (es) | 2020-04-27 |
| WO2015006728A2 (en) | 2015-01-15 |
| BR112016000585A2 (pt) | 2018-03-20 |
| US20160237116A1 (en) | 2016-08-18 |
| JP2016526574A (ja) | 2016-09-05 |
| US9359400B2 (en) | 2016-06-07 |
| EP3613755A1 (en) | 2020-02-26 |
| US10975120B2 (en) | 2021-04-13 |
| US20150017192A1 (en) | 2015-01-15 |
| MX2016000393A (es) | 2016-10-26 |
| JP6739333B2 (ja) | 2020-08-12 |
| CN105593238A (zh) | 2016-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016000393A (es) | Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana. | |
| MX375524B (es) | Anticuerpos anti-axl. | |
| EA201492101A1 (ru) | Антитела против fcrn | |
| EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
| EA201591515A1 (ru) | Полипептиды il-22, химерные белки il-22 fc и их применение | |
| EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
| MX2017008978A (es) | Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos. | |
| JO3519B1 (ar) | تركيبات أجسام مضادة لأجل cdh19 و cd3 | |
| EA201600474A1 (ru) | Комбинированная терапия с использованием антитела к ang2 и агониста cd40 | |
| EA201391041A1 (ru) | Растворимые в воде мембранные белки и способы их получения и применения | |
| MX376058B (es) | Uso de peptidos glp-1 de accion prolongada. | |
| PH12015501846A1 (en) | Novel antibody conjugates and uses thereof | |
| UY34254A (es) | Proteínas y péptidos modificados. | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| DK2831241T3 (da) | Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression. | |
| EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
| EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
| EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 | |
| UY35444A (es) | Anticuerpos anti-tnf alfa mutados y métodos para su utilización | |
| EA201690992A1 (ru) | Антитела, специфичные к fcrn | |
| EA201201016A1 (ru) | Антидоты антикоагулянтов | |
| EA201591974A1 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
| EA201690503A1 (ru) | Антитела |